Health ❯ Healthcare ❯ Medicine

Oncology

Chronic Lymphocytic Leukemia Prostate Cancer Clinical Trials Glioblastoma Lung Cancer Breast Cancer Acute Myeloid Leukemia Multiple Myeloma Lymphoma Cancer Treatment

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

The ruling gives unfit, newly diagnosed patients a home-based alternative that still demands vigilant safety oversight.

Testosterone Loss Linked to Faster Glioblastoma Growth in Men

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Metformin Triggers Exercise-Linked Signal in Prostate Cancer Patients

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

Chinese-Led Bispecifics and ADCs Show Strong Phase III Results at ESMO

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Small-Cell Lung Cancer Forms Functional Synapses With Neurons, Nature Study Finds

Gabapentin Shows Potential to Extend Survival in Glioblastoma Patients

Breakthrough in Cancer Radiotherapy: How DNA Repair Determines Tumor Cell Death

New Mechanism Discovered for Long-Used Cancer Drug 5-Fluorouracil